Early Gestational Glucose Intolerance (EGGI): A Comprehensive Review of Current Evidence and Its Future Directions
Diabetes Asia Journal · 20.07.2026 · 3 (2) · 18-26
DOI: 10.62996/daj.81052026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Asia Journal, online erschienen am 20.07.2026. Verfasst von Sanjev Dave und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Gestational diabetes mellitus (GDM) has traditionally been screened for and diagnosed between 24 and 28 weeks of gestation. Rising rates of obesity, insulin resistance, and first-trimester hyperglycemia — particularly in South Asian and Indian populations — have driven interest in earlier detection.
Objectives
Early Gestational Diabetes Mellitus (eGDM), typically diagnosed before 20–24 weeks using fasting plasma glucose thresholds, has been increasingly studied, most notably through the multicentre Treatment of Booking Gestational Diabetes Mellitus (TOBOGM) trial.
Methods
More recently, Indian investigators have proposed an even earlier construct — Early Gestational Glucose Intolerance (EGGI) — defined as a postprandial blood glucose (PPBG) of ≥110 mg/dl detected at 8–10 weeks of gestation, before fetal beta-cell insulin secretion begins around the 10th–11th week.
Results
This review synthesizes the physiological rationale, proposed diagnostic criteria, available evidence (including the Diabetes in Pregnancy Study Group India [DIPSI] test, the TOBOGM trial, and Indian hospital-based EGGI cohorts), management strategies centered on Medical Nutrition Therapy (MNT) and metformin, and the current controversies and evidence gaps surrounding EGGI.
Conclusion
While early observational and interventional data suggest that identifying and treating EGGI may reduce composite adverse neonatal outcomes, the concept remains outside mainstream international guidelines, and larger randomized trials are needed before EGGI can be recommended for universal, first-trimester screening.
Zitieren
APA
Dave, S., & Tiwari, N. (2026). Early Gestational Glucose Intolerance (EGGI): A Comprehensive Review of Current Evidence and Its Future Directions. Diabetes Asia Journal, 3(2), 18-26. https://doi.org/10.62996/daj.81052026
Vancouver
Dave S, Tiwari N. Early Gestational Glucose Intolerance (EGGI): A Comprehensive Review of Current Evidence and Its Future Directions. Diabetes Asia Journal. 2026;3(2):18-26. doi:10.62996/daj.81052026
BibTeX
@article{Dave2026,
author = {Dave, Sanjev and Tiwari, Nidhi},
title = {Early Gestational Glucose Intolerance (EGGI): A Comprehensive Review of Current Evidence and Its Future Directions},
journal = {Diabetes Asia Journal},
year = {2026},
volume = {3},
number = {2},
pages = {18--26},
doi = {10.62996/daj.81052026}
}
EUVIMED